Bone mineral density in patient with breast cancer
- 作者: Poddubnaya I1, Kizhaev E1, Kolyadina I1, Banov S1, Zhmaeva E1, Secko M1
-
隶属关系:
- ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России, Москва
- 期: 卷 15, 编号 4 (2013)
- 页面: 22-30
- 栏目: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26919
- ID: 26919
如何引用文章
全文:
详细
作者简介
I Poddubnaya
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России, Москвачл.-кор. РАМН, д-р мед. наук, проф., зав. каф. онкологии
E Kizhaev
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России, Москвад-р мед. наук, проф., зав. каф. радиологии
I Kolyadina
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России, Москваканд. мед. наук, ассистент каф. онкологии
S Banov
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России, Москваканд. мед. наук, зав. отд-нием клиники ГБОУ ДПО РМАПО
E Zhmaeva
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России, Москваканд. мед. наук, ассистент каф. радиологии
M Secko
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России, Москвааспирант каф. онкологии
参考
- Поддубная И.В., Колядина И.В., Трофимова О.П. и др. Прогностическое значение локального и системного лечения при раке молочной железы I стадии. Соврем. онкология. 2013; 3: 33–40.
- Baum M, Buzdar A, Cuzick J et al. Anastrozole alone or in combination with tamoxifen vs tamoxifen alone for adjuvant treatment of postmenopausal women with early - stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98: 1802–10.
- Baum M, Hackshaw A, Houghton J et al. Adjuvant goserelin in premenopausal patients with early breast cancer: Results from the ZIPP study. Eur J Cancer 2006; 42: 895–904.
- Body J.J, Bergmann P, Boonen S et al. Management of cancer treatment - induced bone loss in early breast and prostate cancera consensus paper of the Belgian Bone Club. Osteoporos Int 2007; 18: 1439–50.
- Burstein H.J, Prestrud A.A, Seidenfeld J et al. American Society of Clinical Oncology Clinical Practice Guideline: Update on adjuvant endocrine therapy for women with hormone receptor - positive breast cancer. J Clin Oncol 2010; 28: 3784–96.
- Coleman R.E, Banks L.M, Girgis S.I et al. Skeletal effects of exemestane on bone - mineral density bone biomarkers and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study. Lancet Oncol 2007; 8: 119–27.
- Cooke A.L, Metge C, Lix L et al. Tamoxifen use and osteoporotic fracture risk: A population - based analysis. J Clin Oncol 2008; 26: 5227–32.
- Cummings S.R, Bates D, Black D.M. Clinical use of bone densitometry: Scientific review. JAMA 2002; 288: 1889–97.
- Cummings S.R, Nevitt M.C, Browner W.S et al. Risk factors for hip fracture in white women. N Engl J Med 1995; 332: 767–73.
- Cuzick J, Ambroisine L, Davidson N et al. Use of luteinising - hormonereleasing hormone agonists as adjuvant treatment in premenopausal patients with hormone - receptorpositive breast cancer: A meta - analysis of individual patient data from randomised adjuvant trials. Lancet 2007; 369: 1711–23.
- David M, Reid A, Doughty J.B et al. Guidance for the management of breast cancer treatment - induced bone loss: A consensus position statement from a UK Expert Group. Cancer Treatment Reviews 2008; 34: s3.
- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 2005; 365: 1687–717.
- Eastell R, Adams J.E, Coleman R.E et al. Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole Tamoxifen Alone or in Combination Trial 18233230. J Clin Oncol 2008; 26: 1051–7.
- Eidtmann H, de Boer R, Bundred N et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010; 21: 2188–94.
- Ellis G.K, Bone H.G, Chlebowski R et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26: 4875–82.
- Faulkner K.G. Bone matters: Are density increases necessary to reduce fracture risk? J Bone Miner Res 2000; 15: 183–7.
- Geisler J, Lonning P.E. Endocrine effects of aromatase inhibitors and inactivators in vivo: Review of data and method limitations. J Steroid Biochem Mol Biol 2005; 95: 75–81.
- Gnant M.F, Mlineritsch B, Luschin-Ebengreuth G et al. Zoledronic acid prevents cancer treatment - induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone - responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007; 25: 820–8.
- Good P.J, Ennis M, Pritchard K.I et al. Prognostic effects of 25-hydroxyvitamin D Leveis in early breast cancer. J Clin Oncol 2009; 27: 3757–63.
- Azim H.A, Azambuja J.E, Colozza M et al. Long - term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncology 2011; 22: 1939– 47.
- Hillner B.E, Ingle J.N, Chlebowski R.T et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042–57.
- Hofbauer L.C, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292: 490–5.
- Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in combination) trial after completion of 5 year’s adjuvant treatment for breast cancer. Lancet 2005; 365: 60–2.
- Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J Clin 2009; 59: 225–49.
- Lester J.E, Dodwell D, Horsman J.M et al. Current management of treatment - induced bone loss in women with breast cancer treated in the United Kingdom. Br J Cancer 2006; 94: 30–5.
- Lester J.E, Dodwell D, Purohit O.P et al. Prevention of anastrozole - induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008; 14: 6336–42.
- Lewiecki E.M. RANK ligand inhibition with denosumab for the management of osteoporosis. Expert Opin Biol Ther 2006; 6: 1041–50.
- Love R.R, Mazess R.B, Barden H.S et al. Effect of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852–6.
- Marshall D, Johnell O, Wedel H. Meta - analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254–9.
- National Osteoporosis Foundation. http://www.nof.org/osteoporosis/diseasefacts.htm
- Pacifici R. Estrogen cytokines and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996; 11: 1043–51.
- Park-Wyllie L, Mamdani M, Juurlink D et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011; 305: 783–9.
- Perez E.A, Josse R.G, Pritchard K.I et al. Effect of letrozole vs placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA. J Clin Oncol 2006; 24: 3629–35.
- Plevritis S.K, Fryback D.G, Clarke L et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 1784–92.
- Powles T.J, Hickish T, Kanis J.A et al. Effect of tamoxifen on bone mineral density measured by dual - energy x - ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14: 78–84.
- Russell R.G, Watts N.B, Ebetino F.H, Rogers M.J. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19: 733–59.
- Simpson E.R, Dowsett M. Aromatase and its inhibitors: Significance for breast cancer therapy. Recent Prog Horm Res 2002; 57: 317–38.
- Syed Z, Khan A. Bone densitometry: Applications and limitations. J Obstet Gynaecol Can 2002; 24: 476–84.
- Thurlimann B, Keshaviah A, Coates A.S et al. Comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747–57.
- Valachis A, Polyzos N.P, Georgoulias V et al. Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: A meta - analysis. Gynecol Oncol 2010; 117: 139–45.
- Van Poznak C, Hannon R.A, Mackey J.R et al. Prevention of aromatase inhibitor - induced bone loss using risedronate: The SABRE trial. J Clin Oncol 2010; 28: 967–75.
- Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 2006; 24 (4): 675–80.
- Warne G.T, Failey K.F, Hobbs J.B, Martin F.I. Cyclophosphamide - induced ovarian failure. N Engl J Med 1973; 289: 1159–62.
- Warne G.T, Failey K.F, Hobbs J.B, Martin F.I. Cyclophosphamide - induced ovarian failure. N Engl J Med 1973; 289: 1159–62.
- Weitzmann M.N, Pacifici R. Estrogen deficiency and bone loss: An inflammatory tale. J Clin Invest 2006; 116: 1186–94.